Related Experiment Video
Updated: May 10, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Leveraging metabolomics to assess the next generation of temozolomide-based therapeutic approaches for glioblastomas
Patrick-Denis St-Coeur1, Mohamed Touaibia, Miroslava Cuperlovic-Culf
1Department of Chemistry and Biochemistry, Université de Moncton, Canada.
Abstract:
Glioblastoma multiforme (GBM) is the most common adult primary tumor of the central nervous system. The current standard of care for glioblastoma patients involves a combination of surgery, radiotherapy and chemotherapy with the alkylating agent temozolomide. Several mechanisms underlying the inherent and acquired temozolomide resistance have been identified and contribute to treatment failure. Early identification of temozolomide-resistant GBM patients and improvement of the therapeutic strategies available to treat this malignancy are of uttermost importance. This review initially looks at the molecular pathways underlying GBM formation and development with a particular emphasis placed on recent therapeutic advances made in the field. Our focus will next be directed toward the molecular mechanisms modulating temozolomide resistance in GBM patients and the strategies envisioned to circumvent this resistance. Finally, we highlight the diagnostic and prognostic value of metabolomics in cancers and assess its potential usefulness in improving the current standard of care for GBM patients.
Insights
Glioblastoma multiforme (GBM) treatment faces challenges due to temozolomide resistance. This review explores GBM development, resistance mechanisms, and metabolomics for improved diagnostics and therapies.
Area of Science:
- Neuro-oncology
- Cancer biology
- Molecular medicine
Background:
- Glioblastoma multiforme (GBM) is the most common primary adult central nervous system tumor.
- Current treatment involves surgery, radiotherapy, and temozolomide chemotherapy.
- Inherent and acquired temozolomide resistance significantly limits treatment efficacy.
Purpose of the Study:
- To review molecular pathways in GBM development and therapeutic advances.
- To investigate mechanisms of temozolomide resistance in GBM.
- To assess the role of metabolomics in GBM diagnosis, prognosis, and treatment.
Main Methods:
- Literature review of molecular pathways in GBM.
- Analysis of mechanisms contributing to temozolomide resistance.
- Exploration of metabolomics applications in cancer research.
Main Results:
- Identified key molecular pathways in GBM pathogenesis.
- Detailed various mechanisms of temozolomide resistance.
- Highlighted the diagnostic and prognostic potential of metabolomics.
Conclusions:
- Understanding GBM molecular pathways and resistance is crucial for improving outcomes.
- Metabolomics offers promising avenues for early detection and personalized therapy in GBM.
- Novel therapeutic strategies are needed to overcome temozolomide resistance in glioblastoma.
